PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17969380-6	2007	Biguanides and thiazolidinediones (TZDs) are two classes of oral agents for the management of DM2 that improve insulin resistance, and thus have potential cardiovascular benefits beyond glycemic control alone.	Biguanides	0-10	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	94-97	
21298495-6	2012	Additionally, DM2 patients without cancer, who had parents or siblings with DM2, received biguanide metformin versus sulfonylurea derivatives more often than those with breast or endometrial cancer, either with or without family history of DM2.	Biguanides	90-99	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	14-17	
21298495-6	2012	Additionally, DM2 patients without cancer, who had parents or siblings with DM2, received biguanide metformin versus sulfonylurea derivatives more often than those with breast or endometrial cancer, either with or without family history of DM2.	Biguanides	90-99	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	76-79	
21298495-6	2012	Additionally, DM2 patients without cancer, who had parents or siblings with DM2, received biguanide metformin versus sulfonylurea derivatives more often than those with breast or endometrial cancer, either with or without family history of DM2.	Biguanides	90-99	immunoglobulin heavy diversity 1-14 (non-functional)	Homo sapiens	76-79